The sole FDA-approved therapeutic option for autosomal dominant polycystic kidney disease is limited to slowing the progression of the condition

Evolving US policy battles over drug pricing and healthcare affordability, tracking legislation, court rulings, regulatory actions, and industry responses shaping costs, access, and market dynamics.